公开(公告)号：US20190100507A1

公开(公告)日：2019-04-04

申请号：US16085311

申请日：2017-03-16

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hong LIU ,  Jia LI ,  Jiang WANG ,  Mingbo SU ,  Shuni WANG ,  Yubo ZHOU ,  Wei ZHU ,  Wei XU ,  Chunpu LI ,  Hualiang JIANG ,  Kaixian CHEN

IPC: C07D401/12 ,  C07D401/06 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D409/06 ,  C07D417/12 ,  C07D471/04 ,  C07D205/04 ,  C07D265/30 ,  C07D211/38 ,  C07D211/96 ,  A61P35/00

Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.

公开(公告)号：US20230133600A1

公开(公告)日：2023-05-04

申请号：US17796076

申请日：2021-01-28

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Hong LIU ,  Jian LI ,  Jingjing PENG ,  Xiong XIE ,  Wenhao DAI ,  Shulei HU ,  Chunpu LI ,  Leike ZHANG ,  Zhenming JIN ,  Yechun XU ,  Gengfu XIAO ,  Haitao YANG ,  Fang BAI ,  Xi CHENG ,  Hualiang JIANG ,  Kaixian CHEN

IPC: A61K31/404 ,  A61K31/4412 ,  A61K31/4025 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/443 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/4535 ,  A61K31/453 ,  A61K31/4525 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/4155

Abstract: A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor, and/or may be used in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.

公开(公告)号：US20240279177A1

公开(公告)日：2024-08-22

申请号：US18392472

申请日：2023-12-21

Applicant: JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hong LIU ,  Ben NIU ,  Chunpu LI ,  Jianping CHEN ,  Kun HUANG ,  Jiang WANG

IPC: C07D211/60 ,  C07D401/12 ,  C07D409/12

CPC classification number: C07D211/60 ,  C07D401/12 ,  C07D409/12

Abstract: The present invention relates to the fields of medicinal chemistry and pharmaco therapeutics, and specifically to a method for preparing a compound of formula I and a chemically acceptable salt thereof.

公开(公告)号：US20230138310A1

公开(公告)日：2023-05-04

申请号：US17759807

申请日：2020-03-26

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  FRONTIER BIOTECHNOLOGIES INC.

Inventor： Hong LIU ,  Jian LI ,  Wenhao DAI ,  Jingjing PENG ,  Xiong XIE ,  Shulei HU ,  Chunpu LI ,  Yechun XU ,  Haitao YANG ,  Leike ZHANG ,  Haixia SU ,  Hualiang JIANG ,  Zhenming JIN ,  Gengfu XIAO ,  Kaixian CHEN

IPC: C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/12 ,  C07D411/12 ,  C07D471/04 ,  C07D207/12 ,  A61P31/14

Abstract: Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.

公开(公告)号：US20190135818A1

公开(公告)日：2019-05-09

申请号：US16304508

申请日：2017-05-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hualiang JIANG ,  Hong LIU ,  Meiyu GENG ,  Mingyue ZHENG ,  Jing AI ,  Yulan WANG ,  Xiaowei WU ,  Shuangjie LI ,  Xia PENG ,  Chunpu LI ,  Kaixian CHEN ,  Bao WANG

IPC: C07D487/04 ,  A61P35/00

Abstract: The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.